Artigo Revisado por pares

The “Long and Winding Road” of the Disease‐Modifying Effects of Levodopa Has Not Ended Yet

2019; Wiley; Volume: 35; Issue: 3 Linguagem: Inglês

10.1002/mds.27961

ISSN

1531-8257

Autores

Miguel Leal Rato, Olivier Rascol, Joaquim J. Ferreira,

Tópico(s)

Genetic Neurodegenerative Diseases

Resumo

Movement DisordersVolume 35, Issue 3 p. 397-399 Viewpoint The "Long and Winding Road" of the Disease-Modifying Effects of Levodopa Has Not Ended Yet Miguel Leal Rato MD, Miguel Leal Rato MD Neurology, Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, PortugalSearch for more papers by this authorOlivier Rascol MD, PhD, Olivier Rascol MD, PhD Clinical Investigation Center 1436, Department of Clinical Pharmacology and Neurosciences, NS-Park/FCRIN Network, Toulouse, France COEN Center NeuroTOUL, INSERM, University Hospital and University of Toulouse 3, Toulouse, FranceSearch for more papers by this authorJoaquim J. Ferreira MD, PhD, Corresponding Author Joaquim J. Ferreira MD, PhD jferreira@medicina.ulisboa.pt Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal Instituto de Medicina Molecular, Lisbon, Portugal Campus Neurológico Sénior, Torres Vedras, PortugalCorrespondence author: Prof. Joaquim J. Ferreira, Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal; E-mail: jferreira@medicina.ulisboa.ptSearch for more papers by this author Miguel Leal Rato MD, Miguel Leal Rato MD Neurology, Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, PortugalSearch for more papers by this authorOlivier Rascol MD, PhD, Olivier Rascol MD, PhD Clinical Investigation Center 1436, Department of Clinical Pharmacology and Neurosciences, NS-Park/FCRIN Network, Toulouse, France COEN Center NeuroTOUL, INSERM, University Hospital and University of Toulouse 3, Toulouse, FranceSearch for more papers by this authorJoaquim J. Ferreira MD, PhD, Corresponding Author Joaquim J. Ferreira MD, PhD jferreira@medicina.ulisboa.pt Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal Instituto de Medicina Molecular, Lisbon, Portugal Campus Neurológico Sénior, Torres Vedras, PortugalCorrespondence author: Prof. Joaquim J. Ferreira, Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal; E-mail: jferreira@medicina.ulisboa.ptSearch for more papers by this author First published: 24 December 2019 https://doi.org/10.1002/mds.27961Citations: 5 Relevant conflicts of interests/financial disclosures: O.R. reports scientific grants from Agence Nationale de la Recherche, Centre Hospitalier Universitaire de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, Michael J Fox Foundation, Programme Hospitalier de Recherche Clinique, and European Commission (FP7, H2020); has acted as scientific advisor for AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astrazeneca, Bial, Biogen, Britannia, Clevexel, INC Reasearch, Lundbeck, Lupin, Merck, MundiPharma, Neuratris, Neuroderm, Novartis, ONO Pharma, Osmotica, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Sunovion, Théranexus, Takeda, Teva, UCB, XenoPort, and Zambon. J.J.F. has received speaker and consultant fees from Novartis, TEVA, Lundbeck, Solvay, AbbVie, BIAL, Merck-Serono, Grunenthal, Merck Sharp & Dohme, Biogen, Sunovion Pharmaceuticals, Zambon, Affiris and Medtronic. M.L.R. declares no competing interests. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume35, Issue3March 2020Pages 397-399 RelatedInformation

Referência(s)
Altmetric
PlumX